Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.54USD
10:11am EST
Change (% chg)

$-0.00 (-0.02%)
Prev Close
$0.54
Open
$0.52
Day's High
$0.58
Day's Low
$0.52
Volume
15,491
Avg. Vol
117,209
52-wk High
$1.41
52-wk Low
$0.33

Select another date:

Thu, Nov 17 2016

BRIEF-Oncogenex Pharmaceuticals says committed to further reduction in workforce

* Will eliminate 5 positions and estimates that will incur about $750,000 in cash expenditures as a result

BRIEF-Oncogenex Pharmaceuticals reports Q3 loss per share $0.12

* Oncogenex Pharmaceuticals Inc reports financial results for third quarter 2016

BRIEF-Oncogenex says will cut about 55 pct of company's workforce

* Oncogenex - on October 25, 2016, committed to a restructuring of a portion of company's workforce

BRIEF-OncoGenex announces positive survival results from apatorsen Phase 2 trial in metatstatic bladder cancer

* OncoGenex announces positive survival results from apatorsen Phase 2 Borealis-2 trial in metastatic bladder cancer

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer

OncoGenex seeks strategic alternatives after drug study fails

OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.

UPDATE 1-OncoGenex seeks strategic alternatives after drug study fails

Aug 16 OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.

BRIEF-Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint

* Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer

BRIEF-Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million

* Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016

Select another date: